Search Results
Your search for ,USE matches 11186 pages
Showing 2001 - 2050Outcomes After Nonresponse and Relapse in Children and Young Adults Receiving Tisagenlecleucel for B-Cell ALL
In a retrospective study reported in the Journal of Clinical Oncology, Schultz et al found poor survival among children and young adults with lack of response to tisagenlecleucel for B-cell acute lymphoblastic leukemia (ALL). Salvage therapy after relapse was capable of inducing responses, but...
Genetic Variation May Explain Racial Disparity in Esophageal Cancer Cases
Esophageal adenocarcinoma is a type of cancer affecting the mucus-secreting glands of the lower esophagus and is the most common form of esophageal cancer. It is often preceded by Barrett’s metaplasia, a deleterious change in cells lining the esophagus. Though the cause of esophageal adenocarcinoma ...
Financial Burden of High-Cost Targeted Oral Anticancer Drugs Among Medicare Patients
In a study reported in JCO Oncology Practice, Li et al identified elements of increasing financial burden associated with the use of high-cost targeted oral anticancer drugs among Medicare patients between 2011 and 2016. The study used data from the Surveillance, Epidemiology, and End Results...
Unhealthy Gut May Set the Stage for Breast Cancer to Spread, Preclinical Research Reveals
An unhealthy gut triggers changes in normal breast tissue that may help breast cancer metastasize, according to new, early research from the University of Virginia (UVA) Cancer Center published by Feng et al in Cancer Immunology Research. The researchers found that when the gut microbiome is...
Genomic Testing May Aid in Identifying Patients of African Descent With High-Risk Prostate Cancer
Black patients of African descent tend to be diagnosed more frequently with prostate cancer and have higher mortality rates than patients of other races and ethnicities. Despite this substantial disparity, few prospective studies focused on maximizing the recruitment of African American patients...
Overall Survival With Maintenance Olaparib in Newly Diagnosed Patients With Advanced BRCA-Mutated Ovarian Cancer: 7-Year Follow-up
As reported in the Journal of Clinical Oncology by DiSilvestro et al, the 7-year follow-up of the phase III SOLO1/GOG 3004 trial showed a reduction in risk of death by almost half with maintenance olaparib vs placebo in newly diagnosed patients with advanced ovarian cancer and a BRCA1/2 mutation,...
Risk Factors for Heart Failure Among Survivors of Childhood Cancer
In a European study reported in the Journal of Clinical Oncology, de Baat et al identified heart exposure to radiotherapy and cumulative anthracycline doses as factors associated with increased risk of heart failure in survivors of childhood cancers. Survivors who received a mean heart radiotherapy ...
Effectiveness of Dexamethasone for Dyspnea in Patients With Cancer
In a study (ABCD; Alleviating Breathlessness in Cancer Patients with Dexamethasone) reported in The Lancet Oncology, David Hui, MD, MS, MSc, and colleagues found that high-dose dexamethasone did not improve dyspnea compared with placebo in patients with cancer and was associated with greater...
Can a Navigation Program Lower Care Costs for Patients With Cancer?
A cancer navigation program can reduce overall costs when deployed in collaboration with a statewide Medicare Advantage health plan across a wide range of practice types, according to findings to be presented by Worland et al at the upcoming 2022 ASCO Quality Care Symposium (Abstract 4). A...
Total Cost of Cancer Care May Be Reduced With Lower-Cost Alternate Drugs Without Compromising Quality of Care
Substituting biosimilars, generics, and clinically appropriate lower-cost drugs for established, costlier drugs was shown to be an effective way to reduce the total cost of care, by 5% or so, while maintaining the quality of care for patients with cancer. Even small shifts toward lower-cost drugs...
A Physicist Father Inspired a Love of Science in Oncology Researcher Stanton L. Gerson, MD
In this installment of the Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Stanton (“Stan”) L. Gerson, MD, Dean and Senior Vice President for Medical Affairs, School of Medicine, and Acting Director of the Case Comprehensive Cancer Center and National Center for...
Diversify Cancer Clinical Trials With New Recruitment and Retention Resources
ASCO and the Association of Community Cancer Centers (ACCC) jointly released two resources to help research sites increase racial and ethnic equity, diversity, and inclusion (EDI) in cancer clinical trials. The Just ASK™ Increasing Diversity in Cancer Clinical Research: An ACCC-ASCO Training...
Determining Prognosis in Aggressive Lymphomas: Integrating Liquid Biopsy Into Imaging Assessment
The incorporation of blood-based measurements—ie, “liquid biopsies”—into imaging assessment may refine the accuracy of prognosis in aggressive lymphomas, as described by David Kurtz, MD, PhD, Assistant Professor in the Division of Oncology, Stanford University Medical Center, in a talk at the 2022...
Expert Point of View: Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD
Discussant of the exploratory analysis of the POSEIDON trial, Chia Puey Ling, MBBS, MMed, MRCP, FRACP, PhD, a medical oncologist at Tan Tock Seng Hospital, Singapore, noted that although 30% of the mutation-evaluable population had KRAS mutations, only a small percentage of patients had co-mutated...
Exploratory Analysis of POSEIDON: Chemoimmunotherapy Regimen May Offer Survival Benefit in Subgroups of Metastatic NSCLC
The addition of the CTLA-4 inhibitor tremelimumab to durvalumab and chemotherapy in the first-line setting has already demonstrated an overall survival and progression-free survival benefit vs chemotherapy alone in patients with metastatic non–small cell lung cancer (NSCLC). According to data...
Patients With Multiple Myeloma May Face CAR T-Cell Shortages
From microchips to automobiles, people in the United States are experiencing shortages of all kinds of products, and oncology treatments are no exception. In particular, shortages related to chimeric antigen receptor (CAR) T-cell therapy have been reported, most acutely, for B-cell maturation...
Trastuzumab Deruxtecan for Advanced HER2-Mutant NSCLC
On August 11, 2022, fam-trastuzumab deruxtecan-nxki was granted accelerated approval for unresectable or metastatic non–small cell lung cancer (NSCLC) with tumors that have activating HER2 mutations, as detected by a U.S. Food and Drug Administration (FDA)-approved test and who have received a...
Capmatinib for Metastatic NSCLC With MET Exon 14 Skipping Mutation
On August 10, 2022, capmatinib was granted regular approval for patients with metastatic non–small cell lung cancer (NSCLC) with tumors having a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by a U.S. Food and Drug Administration–approved test.1...
Expert Point of View: Benjamin Besse, MD, PhD
Discussant of the IMpower010 abstract, Benjamin Besse, MD, PhD, Professor and Head of Clinical Research at Institute Gustave Roussy, Villejuif, France, said there is enough evidence to use adjuvant immunotherapy in stage II–IIIA resected non–small cell lung cancer (NSCLC), calling the increased...
Expert Point of View: Kara N. Maxwell, MD, PhD
Abstract discussant Kara N. Maxwell, MD, PhD, Assistant Professor of Medicine and Genetics at the University of Pennsylvania Perelman School of Medicine, highlighted evidence showing that some lung cancer is inherited. The Nordic Twin Study identified an 18% heritability of lung cancer, she said,...
Is Germline Testing Warranted for All Patients With Lung Cancer?
Germline testing may be warranted for all patients with lung cancer, according to research presented during the August 2022 ASCO Plenary Series by Renato G. Martins, MD, MPH, Chair of Hematology Oncology and Palliative Care at Virginia Commonwealth University Massey Cancer Center, Richmond.1 The...
AACR Cancer Progress Report 2022 Shows Cancer Mortality Rates Continue to Decline, but Challenges Remain
Advances in more effective treatment and early detection diagnostics, coupled with reductions in smoking rates, have resulted in a 32% decline in cancer mortality in the United States since 1991, translating into nearly 3.5 million lives saved, according to the newly released American Association...
New, Long-Term Opioid Use After Lung Cancer Surgery Linked to Reduced 2-Year Survival
New, long-term use of opioids after lung cancer surgery was linked to a 40% increased risk of death from any cause within the following 2 years, according to findings published by Oh et al in the journal Regional Anesthesia & Pain Medicine. Persistent postoperative pain has been reported in up...
Pafolacianine for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer
In a phase III trial reported in the Journal of Clinical Oncology, Janos L. Tanyi, MD, PhD, and colleagues found that use of pafolacianine infusion for intraoperative imaging improved the detection of lesions in patients with folate receptor–positive ovarian cancer, compared with using white light...
Neoadjuvant Atezolizumab May Be Safe, Effective Option for Localized Non–Small Cell Lung Cancer
New data show that the immuno-oncology drug atezolizumab may be a safe and effective treatment for patients with stage IB to IIIB non–small cell lung cancer (NSCLC) prior to surgery, according to a study led by researchers with The Ohio State University Comprehensive Cancer Center–Arthur G. James...
Adjuvant Nivolumab With or Without Ipilimumab in Patients With Resected Stage IV Melanoma With No Evidence of Disease
As reported in The Lancet by Livingstone et al, the final analysis of the German phase II IMMUNED trial showed significantly improved recurrence-free survival with adjuvant nivolumab/ipilimumab and nivolumab alone vs placebo in patients with resected stage IV melanoma who had no evidence of disease ...
ctDNA Analysis of Acquired EGFR Resistance Alterations With First-Line Cetuximab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
In a circulating tumor DNA (ctDNA) substudy from the CALGB/SWOG-80405/Alliance trial reported in the Journal of Clinical Oncology, Kanwal Raghav, MD, MBBS, and colleagues found that first-line use of the anti-EGFR antibody cetuximab combined with chemotherapy was associated with only a small number ...
Preclinical Study Finds New Synthetic Lethal Agent Could Be Potential Treatment for Pancreatic Cancer
Researchers at The Marvin and Concetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center have found that a new synthetic lethal agent could be an effective treatment for pancreatic cancers with DNA damage repair (DDR) defects. Igor Astsaturov, MD, PhD, a co-director of the Institute...
Individuals of Mexican Descent May Have Higher Risk of Liver Cancer With Each Successive Generation
Studies show that Hispanic individuals have higher incidence rates of developing liver cancer and higher mortality rates—by 50% or more—than non-Hispanic White individuals for several cancers, including liver cancer. A new study investigating hepatocellular carcinoma among successive generations of ...
New Study Shows Sugar-Sweetened Drinks May Increase Risk of Cancer Mortality
In a large study led by researchers at the American Cancer Society (ACS), men and women who drank two or more servings of sugar-sweetened beverages per day had a 5% increased risk of death from an obesity-related cancer, including gastrointestinal, postmenopausal breast, endometrial, and kidney...
National Lung Screening Trial Results Highlight Importance of Lifelong Follow-up
Approximately 6% of patients with stage I to III lung cancer develop a second primary lung cancer within 5 years of their initial diagnosis, according to research presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer.1 Analysis of data...
Costs of Cancer Treatment for Younger, Privately Insured Patients
A new, large study led by researchers at the American Cancer Society (ACS) and The University of Texas MD Anderson Cancer Center showed the rising costs of cancer treatment led to increases in total costs of care, and when compounded with greater cost-sharing, increased out-of-pocket costs for...
Cost-Effectiveness of Chemotherapy Sequences in Metastatic Breast Cancer According to Prior Therapy Exposure
In a modeling study reported in the Journal of Clinical Oncology, Stephanie B. Wheeler, PhD, MPH, and colleagues identified the most cost-effective sequences of single-agent chemotherapy regimens among patients with endocrine-refractory or triple-negative metastatic breast cancer according to prior ...
Use of Trimodality Therapy in Stage II/III Rectal Cancer in the United States: 10-Year Period
In a retrospective cohort study reported in JAMA Oncology, Hagen F. Kennecke, MD, and colleagues found that among U.S. patients with clinical stage II/III rectal cancer diagnosed between 2006 and 2016 who received trimodality therapy, use of postoperative chemoradiation therapy (CRT) decreased and...
Lung Cancer Screening Increases Percentage of Stage I Cases Detected, While Reducing Percentage of Stage IV Cases Detected
Implementing lung cancer screening at four diverse health-care systems resulted in an 8.4% increase in the number of stage I lung cancers detected and a 6.6% decrease in the detection of stage IV disease, according to research published by Vachani et al in the Journal of Thoracic Oncology. The...
Study Explores Link Between Use of Antipsychotic Agents and Increased Breast Cancer Risk
A research team from the Centre for Safe Medication Practice and Research (CSMPR) in the Department of Pharmacology and Pharmacy at the University of Hong Kong (HKUMed) conducted a systematic review and meta-analysis of observational studies with over 2 million individuals and estimated a moderate...
Updated Results From the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutated NSCLC
Newly released results from the phase III ADAURA trial revealed that osimertinib yielded a 5.5-year median disease-free survival in the postsurgical treatment of patients with EGFR-mutated non–small cell lung cancer (NSCLC), and nearly three in four patients treated with adjuvant osimertinib were...
PRESTO: Treatment Beyond Androgen-Deprivation Therapy for Relapsed Patients With High-Risk Prostate Cancer
Aggarwal et al presented data from PRESTO (AFT-19) at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA63), the first trial to evaluate whether intensifying treatment beyond androgen-deprivation therapy (ADT) by adding apalutamide with or without abiraterone acetate plus...
TROPiCS-02 Update: Sacituzumab Govitecan Improves Overall Survival in Previously Treated Patients With Hormone Receptor–Positive, HER2-Negative Breast Cancer
An overall survival benefit has now emerged for sacituzumab govitecan-hziy in patients with previously treated hormone receptor–positive/HER2-negative locally recurrent inoperable or metastatic breast cancer, according to a planned second interim analysis of the phase III TROPiCS-02 trial. These...
Nirogacestat for Progressive Desmoid Tumors: DeFi Trial
Significant improvements in progression-free survival and response rate—combined with reduced symptoms and better quality of life—were reported as outcomes of a new treatment approach for patients with desmoid tumors, benign but locally aggressive and invasive soft-tissue tumors. Through targeting...
COSMIC-313: Cabozantinib, Nivolumab, and Ipilimumab in Previously Untreated Patients With Advanced Renal Cell Carcinoma
A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by Toni K. Choueiri, MD. Dr. Choueiri, who is the Director of the Lank Center for Genitourinary Cancer at...
PROSPER RCC: Neoadjuvant Nivolumab Prior to Nephrectomy Followed by Additional Nivolumab in Patients With Renal Cell Carcinoma
The ECOG-ACRIN Cancer Research Group presented data from PROSPER RCC (EA8143), the first randomized phase III trial of neoadjuvant immunotherapy in patients with kidney cancer, at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA67). Patients with high-risk renal cell...
Researchers Examine How Air Pollution May Drive Lung Cancer in Never-Smokers
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and the development of novel therapies, according to late-breaking data reported by Charles Swanton, MBBS, ...
ESMO and EONS Announce Launch of PrEvCan
On September 9, the European Society for Medical Oncology (ESMO), together with the European Oncology Nursing Society (EONS), announced the launch of the Europe-wide “Cancer Prevention Across Europe” campaign (PrEvCan) aimed at reducing the burden of cancer. The announcement was made at the opening ...
EQRx Pricing Strategy: Not a Win for Everyone but a Key First Step to Expand Access to Cancer Care
EQRx is an economics professor’s dream company. It is the perfect example of the principle of substitution. EQRx provides quality, lower-cost drugs in high-cost categories that may substitute for the higher-priced options. Although the profit margin for each drug unit is smaller than the...
Neurosurgeon Ashish Shah, MD, Returns to Sylvester to Head Clinical Trials and Translational Research on Brain Tumors
Ashish Shah, MD, has assumed the newly created position of Director of Clinical Trials and Translational Research and principal investigator in the Section of Virology and Immunotherapy at Sylvester Comprehensive Cancer Center’s Brain Tumor Initiative (BTI) at the University of Miami Miller School ...
ASCO Updated Guideline of Biomarkers in Metastatic Breast Cancer Supports PIK3CA, BRCA1/2, PD-L1 Testing
ASCO has issued a new practice guideline update on the use of biomarkers in the management of metastatic breast cancer.1 The updated guideline revisits recommendations from the 2015 guideline and addresses topics that have emerged since then in the move toward personalized medicine in metastatic...
Pebbles Fagan, PhD, MPH, Joins Leadership Team at UAMS Winthrop P. Rockefeller Cancer Institute-
Pebbles Fagan, PhD, MPH, has been named Director of the Center for the Study of Tobacco at the Fay W. Boozman College of Public Health at the University of Arkansas for Medical Sciences (UAMS). Dr. Fagan will serve as Professor in the Department of Health Behavior and Health Education in the...
Study Examines Efficacy of T-Cell Redirection Therapies for Patients With Relapsed Multiple Myeloma
Mount Sinai researchers have published results that show alternate therapeutic options for patients with multiple myeloma after first-line treatment with bispecific antibodies fails. While new T cell–based immunotherapies, or “T-cell redirection” therapies, such as chimeric antigen receptor (CAR)...
Adjuvant Pembrolizumab in Patients With Clear Cell Renal Cell Carcinoma and Increased Risk of Recurrence: 30-Month Follow-up of KEYNOTE-564
As reported in The Lancet Oncology by Thomas Powles, MD, PhD, and colleagues, the 30-month follow-up of the phase III KEYNOTE-564 trial showed a continued disease-free survival benefit with adjuvant pembrolizumab vs placebo in patients with clear cell renal cell carcinoma who are at increased risk...
